Review



anti e2f1  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Proteintech anti e2f1
    Anti E2f1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 190 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/e2f1/E2F1+Antibody/pm41826982-101-36-38
    Average 96 stars, based on 190 article reviews
    anti e2f1 - by Bioz Stars, 2026-11
    96/100 stars

    Images

    Related Articles

    Immunoprecipitation:

    Article Title: A multi-omics integration identifies ENY2 hypomethylation as a driver of immunosuppression and progression in breast cancer.
    Article Snippet: Aberrant DNA methylation contributes to breast cancer (BC) progression and immune microenvironment dysregulation, but its underlying epigenetic-immune crosstalk remains poorly defined.. This study constructed a methylation-driven prognostic Jo ur na l P re -p ro of Journal Pre-proof signature in BC using the SIMPO algorithm and Cox regression with TCGA cohort data, validated externally in the GSE76427 cohort.. Bioinformatic analyses including GSEA, CIBERSORT and TIMER were applied to characterize the immune microenvironment.

    Cell-Signaling:

    Article Title: A multi-omics integration identifies ENY2 hypomethylation as a driver of immunosuppression and progression in breast cancer.
    Article Snippet: Aberrant DNA methylation contributes to breast cancer (BC) progression and immune microenvironment dysregulation, but its underlying epigenetic-immune crosstalk remains poorly defined.. This study constructed a methylation-driven prognostic Jo ur na l P re -p ro of Journal Pre-proof signature in BC using the SIMPO algorithm and Cox regression with TCGA cohort data, validated externally in the GSE76427 cohort.. Bioinformatic analyses including GSEA, CIBERSORT and TIMER were applied to characterize the immune microenvironment.

    other:

    Article Title: SNX1 inhibits human ovarian cancer progression via regulation of the cell cycle, apoptosis and migration.
    Article Snippet: Equal amounts of protein (30 μg) were separated by 10% SDS-PAGE (G2043-50T, Servicebio) and transferred to nitrocellulose membranes (Millipore).

    Plasmid Preparation:

    Article Title: E2F1-mediated 53BP2 lactylation stabilizes p53 to induce cochlear hair cell apoptosis in mouse age-related hearing loss.
    Article Snippet: .. Reagents, antibodies, and plasmid constructs The following primary antibodies were used: anti-E2F1 (1:1000, Proteintech, 66515-1-Ig), anti-53BP2 (1:1000, Abcam, ab236448), anti-p53 (1:1000, Proteintech, 10442-1-AP), antip300 (1:1000, Abcam, ab275378), anti-lactylated-lysine (1:1000, PTM Bio, PTM1429RM), anti-β-actin (1:5000, Sigma-Aldrich, A5441), anti-Myo7a (1:500, Abcam, ab150386), anti-cleaved caspase-3 (1:1000, Cell Signaling Technology, #9661), antiubiquitin (1:5000, Proteintech, 80992-1-RR) and anti-Bax (1:1000, Cell Signaling Technology, #2772). .. Secondary antibodies included HRP-conjugated goat anti-rabbit IgG (1:5000, Cell Signaling Technology, #7074) and HRP-conjugated goat anti-mouse IgG (1:5000, Cell Signaling Technology, #7076).

    Construct:

    Article Title: E2F1-mediated 53BP2 lactylation stabilizes p53 to induce cochlear hair cell apoptosis in mouse age-related hearing loss.
    Article Snippet: .. Reagents, antibodies, and plasmid constructs The following primary antibodies were used: anti-E2F1 (1:1000, Proteintech, 66515-1-Ig), anti-53BP2 (1:1000, Abcam, ab236448), anti-p53 (1:1000, Proteintech, 10442-1-AP), antip300 (1:1000, Abcam, ab275378), anti-lactylated-lysine (1:1000, PTM Bio, PTM1429RM), anti-β-actin (1:5000, Sigma-Aldrich, A5441), anti-Myo7a (1:500, Abcam, ab150386), anti-cleaved caspase-3 (1:1000, Cell Signaling Technology, #9661), antiubiquitin (1:5000, Proteintech, 80992-1-RR) and anti-Bax (1:1000, Cell Signaling Technology, #2772). .. Secondary antibodies included HRP-conjugated goat anti-rabbit IgG (1:5000, Cell Signaling Technology, #7074) and HRP-conjugated goat anti-mouse IgG (1:5000, Cell Signaling Technology, #7076).

    Western Blot:

    Article Title: Targeting MYC in T-Cell lymphoma via epigenetic modulation with a small-molecule inhibitor.
    Article Snippet: .. AR TIC LE IN PR ES S ARTICLE IN PRESS The primary antibodies used in our study for western blotting were anti-MYC (1:1000; CST, Cat# 9402), anti-YB-1 (1:1000; Abcam, Cat# ab76149), anti-p53 (1:1000; Abcam, Cat# ab26), anti-E2F1 (1:1000; Proteintech, Cat# 66515-1-IG), Anti-H3K4me3 (1:1000; PTM BIO, Cat# PTM-613), Anti-H3K9me3 (1:1000; PTM BIO, Cat# PTM-616), Anti-H3K27me3 (1:1000; PTM BIO, Cat# PTM-647RM), Anti-H3K27ac (1:1000; PTM BIO, Cat# PTM-116RM), Anti-H3K9ac (1:1000; PTM BIO, Cat# PTM-112RM), Anti-H3K9la (1:1000; PTM BIO, Cat# PTM-1419RM), Anti-H3K14la (1:1000; PTM BIO, Cat# PTM-1414RM), Anti-H3K18la (1:1000; PTM BIO, Cat# PTM1406RM), Anti-H4K12la (1:1000; PTM BIO, Cat# PTM-1411RM), Anti-H4K16la (1:1000; PTM BIO, Cat# PTM-1417RM), Anti-Histone H3 (1:1000; CST, Cat# 9715), Anti-Histone H4 (1:1000; PTM BIO, Cat# PTM-1015RM), anti-Flag-Tag (1:1000; CST, Cat# 8146), antiMyc-tag (1:1000; CST, Cat# 2278), anti-HA-Tag (1:1000; CST, Cat# 3724), anti-p300 (1:1000; Abcam, Cat# ab275378), anti-CBP (1:1000; CST, Cat# 7389), anti-KAT8 (1:1000; CST, Cat# 46862), anti-AARS1 (1:1000; Proteintech, Cat# 67909-1-IG), anti-AARS2 (1:1000; Proteintech, Cat# 22696-1-IG), anti-UCHL3 (1:1000; Abcam, Cat# ab241490), anti-α-tubulin (1:2000; Proteintech, Cat# 11224-1-AP). ..

    Staining:

    Article Title: Histone modification-regulated LncRNA DLEU1 interacts with ASCC2/ALKBH3 complex to drive DNA repair, antioxidant homeostasis and glucose metabolism in gastric cancer.
    Article Snippet: The images from the two groups were separately overlaid and analyzed using HALO software (Indica Labs, USA). .. The staining sequence and dye combination are as follows: DLEU1 probe (NR_109973.1, 5-1627, working solution, Alpha X Bio, China) - TSA520; E2F1 (1/200 dilution, Proteintech, Cat. #66515-1-Ig, RRID: AB_2881878) - TSA480; ALKBH3 (1/200 dilution, Proteintech, Cat. #12292-1-AP, RRID: AB_11125161) - TSA620; and ASCC2 (1/200 dilution, Proteintech, Cat.#11529-1-AP, RRID: AB_2059358) - TSA780. ..

    Article Title: Histone modification-regulated LncRNA DLEU1 interacts with ASCC2/ALKBH3 complex to drive DNA repair, antioxidant homeostasis and glucose metabolism in gastric cancer
    Article Snippet: The images from the two groups were separately overlaid and analyzed using HALO software (Indica Labs, USA). .. The staining sequence and dye combination are as follows: DLEU1 probe ( NR_109973.1 , 5-1627, working solution, Alpha X Bio, China) - TSA520; E2F1 (1/200 dilution, Proteintech, Cat. #66515-1-Ig, RRID: AB_2881878) - TSA480; ALKBH3 (1/200 dilution, Proteintech, Cat. #12292-1-AP, RRID: AB_11125161) - TSA620; and ASCC2 (1/200 dilution, Proteintech, Cat.#11529-1-AP, RRID: AB_2059358) - TSA780. ..

    Sequencing:

    Article Title: Histone modification-regulated LncRNA DLEU1 interacts with ASCC2/ALKBH3 complex to drive DNA repair, antioxidant homeostasis and glucose metabolism in gastric cancer.
    Article Snippet: The images from the two groups were separately overlaid and analyzed using HALO software (Indica Labs, USA). .. The staining sequence and dye combination are as follows: DLEU1 probe (NR_109973.1, 5-1627, working solution, Alpha X Bio, China) - TSA520; E2F1 (1/200 dilution, Proteintech, Cat. #66515-1-Ig, RRID: AB_2881878) - TSA480; ALKBH3 (1/200 dilution, Proteintech, Cat. #12292-1-AP, RRID: AB_11125161) - TSA620; and ASCC2 (1/200 dilution, Proteintech, Cat.#11529-1-AP, RRID: AB_2059358) - TSA780. ..

    Article Title: Histone modification-regulated LncRNA DLEU1 interacts with ASCC2/ALKBH3 complex to drive DNA repair, antioxidant homeostasis and glucose metabolism in gastric cancer
    Article Snippet: The images from the two groups were separately overlaid and analyzed using HALO software (Indica Labs, USA). .. The staining sequence and dye combination are as follows: DLEU1 probe ( NR_109973.1 , 5-1627, working solution, Alpha X Bio, China) - TSA520; E2F1 (1/200 dilution, Proteintech, Cat. #66515-1-Ig, RRID: AB_2881878) - TSA480; ALKBH3 (1/200 dilution, Proteintech, Cat. #12292-1-AP, RRID: AB_11125161) - TSA620; and ASCC2 (1/200 dilution, Proteintech, Cat.#11529-1-AP, RRID: AB_2059358) - TSA780. ..



    Similar Products

    94
    Genecopoeia e2f1
    <t>E2F1</t> transcriptionally activates TRIP13 to drive Palbociclib resistance in prostate cancer. In TCGA prostate cancer, samples were stratified into high and low TRIP13 expression groups. Differential expression analysis was performed, followed by GSEA enrichment analysis. In the bubble plot, different colors represent NES values, while bubble sizes correspond to the log-adjusted P -values (A) . Spearman correlation plots showing the relationship between E2F1 and TRIP13, panels: (B) TCGA prostate cancer data, (C) PRAD_SU2C_2019 data. (D) Ominer network tool prediction of potential transcription factors for TRIP13. (E) Chip-Seq analysis of E2F1 binding to the TRIP13 promoter region from Chip-Atlas. (F) GPSAdb data indicate reduced TRIP13 expression following E2F1 knockdown. Different colors represent different LogFC. (G) PC-3 cells were transfected with specified shRNA for 72 hours, followed by puromycin selection. These cells were treated with collected for ChIP-qPCR analysis using IgG or E2F1 antibodies. Data represent the mean ± SEM from three independent experiments. ** indicates P < 0.01, *** indicates P < 0.001. (H, I) PC-3 and C4-2 cells were transfected with specified shRNA for 72 hours. After puromycin screening, cells were subjected to western blot analysis (H) and RT-qPCR assay (I) . Data represent the mean ± SEM from three independent experiments. ** indicates P < 0.01, *** indicates P < 0.001. (J, K) PC-3 and C4-2 cells were transfected with designated plasmids for 24 hours. Following puromycin screening, cells underwent western blot analysis (J) and RT-qPCR assay (K) . Data are presented as the mean ± SEM from three independent experiments. *** indicates P < 0.001. (L) The sequence and location of the E2F1 binding peak in the TRIP13 promoter. WT, wild type, MUT, mutant. (M) PC-3 cells were transfected with indicated plasmid for 24 h. After puromycin selection, the cells were harvested and the activity of the TRIP13 promoters was measured. Data are presented as the mean ± SEM from three independent experiments. ** indicates P < 0.01, ns, not significant. (N) PC-3 and C4-2 cells were transfected with specified shRNA for 72 hours and indicated plasmid for 24 h, followed by puromycin selection. The cells were then treated with incremental doses of palbociclib for 24 hours and subjected to CCK-8 assays. Data were expressed as the mean ± SEM and repeated three times. Statistical significance was determined using the indicated tests, with P <0.05 considered significant.
    E2f1, supplied by Genecopoeia, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/e2f1/E2F1+Rabbit+mAb/pmc13143902-68-20-9
    Average 94 stars, based on 1 article reviews
    e2f1 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology mouse anti e2f1 kh95
    <t>E2F1</t> transcriptionally activates TRIP13 to drive Palbociclib resistance in prostate cancer. In TCGA prostate cancer, samples were stratified into high and low TRIP13 expression groups. Differential expression analysis was performed, followed by GSEA enrichment analysis. In the bubble plot, different colors represent NES values, while bubble sizes correspond to the log-adjusted P -values (A) . Spearman correlation plots showing the relationship between E2F1 and TRIP13, panels: (B) TCGA prostate cancer data, (C) PRAD_SU2C_2019 data. (D) Ominer network tool prediction of potential transcription factors for TRIP13. (E) Chip-Seq analysis of E2F1 binding to the TRIP13 promoter region from Chip-Atlas. (F) GPSAdb data indicate reduced TRIP13 expression following E2F1 knockdown. Different colors represent different LogFC. (G) PC-3 cells were transfected with specified shRNA for 72 hours, followed by puromycin selection. These cells were treated with collected for ChIP-qPCR analysis using IgG or E2F1 antibodies. Data represent the mean ± SEM from three independent experiments. ** indicates P < 0.01, *** indicates P < 0.001. (H, I) PC-3 and C4-2 cells were transfected with specified shRNA for 72 hours. After puromycin screening, cells were subjected to western blot analysis (H) and RT-qPCR assay (I) . Data represent the mean ± SEM from three independent experiments. ** indicates P < 0.01, *** indicates P < 0.001. (J, K) PC-3 and C4-2 cells were transfected with designated plasmids for 24 hours. Following puromycin screening, cells underwent western blot analysis (J) and RT-qPCR assay (K) . Data are presented as the mean ± SEM from three independent experiments. *** indicates P < 0.001. (L) The sequence and location of the E2F1 binding peak in the TRIP13 promoter. WT, wild type, MUT, mutant. (M) PC-3 cells were transfected with indicated plasmid for 24 h. After puromycin selection, the cells were harvested and the activity of the TRIP13 promoters was measured. Data are presented as the mean ± SEM from three independent experiments. ** indicates P < 0.01, ns, not significant. (N) PC-3 and C4-2 cells were transfected with specified shRNA for 72 hours and indicated plasmid for 24 h, followed by puromycin selection. The cells were then treated with incremental doses of palbociclib for 24 hours and subjected to CCK-8 assays. Data were expressed as the mean ± SEM and repeated three times. Statistical significance was determined using the indicated tests, with P <0.05 considered significant.
    Mouse Anti E2f1 Kh95, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/e2f1/E2F-1+Antibody/pmc13774038-228-83-87
    Average 96 stars, based on 1 article reviews
    mouse anti e2f1 kh95 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    Proteintech e2f1
    <t>E2F1</t> transcriptionally activates TRIP13 to drive Palbociclib resistance in prostate cancer. In TCGA prostate cancer, samples were stratified into high and low TRIP13 expression groups. Differential expression analysis was performed, followed by GSEA enrichment analysis. In the bubble plot, different colors represent NES values, while bubble sizes correspond to the log-adjusted P -values (A) . Spearman correlation plots showing the relationship between E2F1 and TRIP13, panels: (B) TCGA prostate cancer data, (C) PRAD_SU2C_2019 data. (D) Ominer network tool prediction of potential transcription factors for TRIP13. (E) Chip-Seq analysis of E2F1 binding to the TRIP13 promoter region from Chip-Atlas. (F) GPSAdb data indicate reduced TRIP13 expression following E2F1 knockdown. Different colors represent different LogFC. (G) PC-3 cells were transfected with specified shRNA for 72 hours, followed by puromycin selection. These cells were treated with collected for ChIP-qPCR analysis using IgG or E2F1 antibodies. Data represent the mean ± SEM from three independent experiments. ** indicates P < 0.01, *** indicates P < 0.001. (H, I) PC-3 and C4-2 cells were transfected with specified shRNA for 72 hours. After puromycin screening, cells were subjected to western blot analysis (H) and RT-qPCR assay (I) . Data represent the mean ± SEM from three independent experiments. ** indicates P < 0.01, *** indicates P < 0.001. (J, K) PC-3 and C4-2 cells were transfected with designated plasmids for 24 hours. Following puromycin screening, cells underwent western blot analysis (J) and RT-qPCR assay (K) . Data are presented as the mean ± SEM from three independent experiments. *** indicates P < 0.001. (L) The sequence and location of the E2F1 binding peak in the TRIP13 promoter. WT, wild type, MUT, mutant. (M) PC-3 cells were transfected with indicated plasmid for 24 h. After puromycin selection, the cells were harvested and the activity of the TRIP13 promoters was measured. Data are presented as the mean ± SEM from three independent experiments. ** indicates P < 0.01, ns, not significant. (N) PC-3 and C4-2 cells were transfected with specified shRNA for 72 hours and indicated plasmid for 24 h, followed by puromycin selection. The cells were then treated with incremental doses of palbociclib for 24 hours and subjected to CCK-8 assays. Data were expressed as the mean ± SEM and repeated three times. Statistical significance was determined using the indicated tests, with P <0.05 considered significant.
    E2f1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/e2f1/E2F1+Antibody/pm42880560-75-15-16
    Average 96 stars, based on 1 article reviews
    e2f1 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    OriGene e2f1 nm 005225 human tagged orf clone
    <t>E2F1</t> transcriptionally activates TRIP13 to drive Palbociclib resistance in prostate cancer. In TCGA prostate cancer, samples were stratified into high and low TRIP13 expression groups. Differential expression analysis was performed, followed by GSEA enrichment analysis. In the bubble plot, different colors represent NES values, while bubble sizes correspond to the log-adjusted P -values (A) . Spearman correlation plots showing the relationship between E2F1 and TRIP13, panels: (B) TCGA prostate cancer data, (C) PRAD_SU2C_2019 data. (D) Ominer network tool prediction of potential transcription factors for TRIP13. (E) Chip-Seq analysis of E2F1 binding to the TRIP13 promoter region from Chip-Atlas. (F) GPSAdb data indicate reduced TRIP13 expression following E2F1 knockdown. Different colors represent different LogFC. (G) PC-3 cells were transfected with specified shRNA for 72 hours, followed by puromycin selection. These cells were treated with collected for ChIP-qPCR analysis using IgG or E2F1 antibodies. Data represent the mean ± SEM from three independent experiments. ** indicates P < 0.01, *** indicates P < 0.001. (H, I) PC-3 and C4-2 cells were transfected with specified shRNA for 72 hours. After puromycin screening, cells were subjected to western blot analysis (H) and RT-qPCR assay (I) . Data represent the mean ± SEM from three independent experiments. ** indicates P < 0.01, *** indicates P < 0.001. (J, K) PC-3 and C4-2 cells were transfected with designated plasmids for 24 hours. Following puromycin screening, cells underwent western blot analysis (J) and RT-qPCR assay (K) . Data are presented as the mean ± SEM from three independent experiments. *** indicates P < 0.001. (L) The sequence and location of the E2F1 binding peak in the TRIP13 promoter. WT, wild type, MUT, mutant. (M) PC-3 cells were transfected with indicated plasmid for 24 h. After puromycin selection, the cells were harvested and the activity of the TRIP13 promoters was measured. Data are presented as the mean ± SEM from three independent experiments. ** indicates P < 0.01, ns, not significant. (N) PC-3 and C4-2 cells were transfected with specified shRNA for 72 hours and indicated plasmid for 24 h, followed by puromycin selection. The cells were then treated with incremental doses of palbociclib for 24 hours and subjected to CCK-8 assays. Data were expressed as the mean ± SEM and repeated three times. Statistical significance was determined using the indicated tests, with P <0.05 considered significant.
    E2f1 Nm 005225 Human Tagged Orf Clone, supplied by OriGene, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/e2f1/pCMV6-Entry+Mammalian+Expression+Vector/10__1038_slash_s41598___026___72087___9-287-0-21
    Average 96 stars, based on 1 article reviews
    e2f1 nm 005225 human tagged orf clone - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    91
    OriGene pcmv6 entry mammalian expression vector
    <t>E2F1</t> transcriptionally activates TRIP13 to drive Palbociclib resistance in prostate cancer. In TCGA prostate cancer, samples were stratified into high and low TRIP13 expression groups. Differential expression analysis was performed, followed by GSEA enrichment analysis. In the bubble plot, different colors represent NES values, while bubble sizes correspond to the log-adjusted P -values (A) . Spearman correlation plots showing the relationship between E2F1 and TRIP13, panels: (B) TCGA prostate cancer data, (C) PRAD_SU2C_2019 data. (D) Ominer network tool prediction of potential transcription factors for TRIP13. (E) Chip-Seq analysis of E2F1 binding to the TRIP13 promoter region from Chip-Atlas. (F) GPSAdb data indicate reduced TRIP13 expression following E2F1 knockdown. Different colors represent different LogFC. (G) PC-3 cells were transfected with specified shRNA for 72 hours, followed by puromycin selection. These cells were treated with collected for ChIP-qPCR analysis using IgG or E2F1 antibodies. Data represent the mean ± SEM from three independent experiments. ** indicates P < 0.01, *** indicates P < 0.001. (H, I) PC-3 and C4-2 cells were transfected with specified shRNA for 72 hours. After puromycin screening, cells were subjected to western blot analysis (H) and RT-qPCR assay (I) . Data represent the mean ± SEM from three independent experiments. ** indicates P < 0.01, *** indicates P < 0.001. (J, K) PC-3 and C4-2 cells were transfected with designated plasmids for 24 hours. Following puromycin screening, cells underwent western blot analysis (J) and RT-qPCR assay (K) . Data are presented as the mean ± SEM from three independent experiments. *** indicates P < 0.001. (L) The sequence and location of the E2F1 binding peak in the TRIP13 promoter. WT, wild type, MUT, mutant. (M) PC-3 cells were transfected with indicated plasmid for 24 h. After puromycin selection, the cells were harvested and the activity of the TRIP13 promoters was measured. Data are presented as the mean ± SEM from three independent experiments. ** indicates P < 0.01, ns, not significant. (N) PC-3 and C4-2 cells were transfected with specified shRNA for 72 hours and indicated plasmid for 24 h, followed by puromycin selection. The cells were then treated with incremental doses of palbociclib for 24 hours and subjected to CCK-8 assays. Data were expressed as the mean ± SEM and repeated three times. Statistical significance was determined using the indicated tests, with P <0.05 considered significant.
    Pcmv6 Entry Mammalian Expression Vector, supplied by OriGene, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/e2f1/E2F1+(NM_005225)+Human+Tagged+ORF+Clone/10__1038_slash_s41598___026___72087___9-287-10-21
    Average 91 stars, based on 1 article reviews
    pcmv6 entry mammalian expression vector - by Bioz Stars, 2026-11
    91/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology anti e2f1
    <t>E2F1</t> transcriptionally activates TRIP13 to drive Palbociclib resistance in prostate cancer. In TCGA prostate cancer, samples were stratified into high and low TRIP13 expression groups. Differential expression analysis was performed, followed by GSEA enrichment analysis. In the bubble plot, different colors represent NES values, while bubble sizes correspond to the log-adjusted P -values (A) . Spearman correlation plots showing the relationship between E2F1 and TRIP13, panels: (B) TCGA prostate cancer data, (C) PRAD_SU2C_2019 data. (D) Ominer network tool prediction of potential transcription factors for TRIP13. (E) Chip-Seq analysis of E2F1 binding to the TRIP13 promoter region from Chip-Atlas. (F) GPSAdb data indicate reduced TRIP13 expression following E2F1 knockdown. Different colors represent different LogFC. (G) PC-3 cells were transfected with specified shRNA for 72 hours, followed by puromycin selection. These cells were treated with collected for ChIP-qPCR analysis using IgG or E2F1 antibodies. Data represent the mean ± SEM from three independent experiments. ** indicates P < 0.01, *** indicates P < 0.001. (H, I) PC-3 and C4-2 cells were transfected with specified shRNA for 72 hours. After puromycin screening, cells were subjected to western blot analysis (H) and RT-qPCR assay (I) . Data represent the mean ± SEM from three independent experiments. ** indicates P < 0.01, *** indicates P < 0.001. (J, K) PC-3 and C4-2 cells were transfected with designated plasmids for 24 hours. Following puromycin screening, cells underwent western blot analysis (J) and RT-qPCR assay (K) . Data are presented as the mean ± SEM from three independent experiments. *** indicates P < 0.001. (L) The sequence and location of the E2F1 binding peak in the TRIP13 promoter. WT, wild type, MUT, mutant. (M) PC-3 cells were transfected with indicated plasmid for 24 h. After puromycin selection, the cells were harvested and the activity of the TRIP13 promoters was measured. Data are presented as the mean ± SEM from three independent experiments. ** indicates P < 0.01, ns, not significant. (N) PC-3 and C4-2 cells were transfected with specified shRNA for 72 hours and indicated plasmid for 24 h, followed by puromycin selection. The cells were then treated with incremental doses of palbociclib for 24 hours and subjected to CCK-8 assays. Data were expressed as the mean ± SEM and repeated three times. Statistical significance was determined using the indicated tests, with P <0.05 considered significant.
    Anti E2f1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/e2f1/E2F-1+Antibody/pm42811076-732-173-174
    Average 96 stars, based on 1 article reviews
    anti e2f1 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    94
    MedChemExpress e2f1
    <t>E2F1</t> transcriptionally activates TRIP13 to drive Palbociclib resistance in prostate cancer. In TCGA prostate cancer, samples were stratified into high and low TRIP13 expression groups. Differential expression analysis was performed, followed by GSEA enrichment analysis. In the bubble plot, different colors represent NES values, while bubble sizes correspond to the log-adjusted P -values (A) . Spearman correlation plots showing the relationship between E2F1 and TRIP13, panels: (B) TCGA prostate cancer data, (C) PRAD_SU2C_2019 data. (D) Ominer network tool prediction of potential transcription factors for TRIP13. (E) Chip-Seq analysis of E2F1 binding to the TRIP13 promoter region from Chip-Atlas. (F) GPSAdb data indicate reduced TRIP13 expression following E2F1 knockdown. Different colors represent different LogFC. (G) PC-3 cells were transfected with specified shRNA for 72 hours, followed by puromycin selection. These cells were treated with collected for ChIP-qPCR analysis using IgG or E2F1 antibodies. Data represent the mean ± SEM from three independent experiments. ** indicates P < 0.01, *** indicates P < 0.001. (H, I) PC-3 and C4-2 cells were transfected with specified shRNA for 72 hours. After puromycin screening, cells were subjected to western blot analysis (H) and RT-qPCR assay (I) . Data represent the mean ± SEM from three independent experiments. ** indicates P < 0.01, *** indicates P < 0.001. (J, K) PC-3 and C4-2 cells were transfected with designated plasmids for 24 hours. Following puromycin screening, cells underwent western blot analysis (J) and RT-qPCR assay (K) . Data are presented as the mean ± SEM from three independent experiments. *** indicates P < 0.001. (L) The sequence and location of the E2F1 binding peak in the TRIP13 promoter. WT, wild type, MUT, mutant. (M) PC-3 cells were transfected with indicated plasmid for 24 h. After puromycin selection, the cells were harvested and the activity of the TRIP13 promoters was measured. Data are presented as the mean ± SEM from three independent experiments. ** indicates P < 0.01, ns, not significant. (N) PC-3 and C4-2 cells were transfected with specified shRNA for 72 hours and indicated plasmid for 24 h, followed by puromycin selection. The cells were then treated with incremental doses of palbociclib for 24 hours and subjected to CCK-8 assays. Data were expressed as the mean ± SEM and repeated three times. Statistical significance was determined using the indicated tests, with P <0.05 considered significant.
    E2f1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/e2f1/E2F-1+Antibody/pm42585696-166-11-14
    Average 94 stars, based on 1 article reviews
    e2f1 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology β actin
    <t>E2F1</t> transcriptionally activates TRIP13 to drive Palbociclib resistance in prostate cancer. In TCGA prostate cancer, samples were stratified into high and low TRIP13 expression groups. Differential expression analysis was performed, followed by GSEA enrichment analysis. In the bubble plot, different colors represent NES values, while bubble sizes correspond to the log-adjusted P -values (A) . Spearman correlation plots showing the relationship between E2F1 and TRIP13, panels: (B) TCGA prostate cancer data, (C) PRAD_SU2C_2019 data. (D) Ominer network tool prediction of potential transcription factors for TRIP13. (E) Chip-Seq analysis of E2F1 binding to the TRIP13 promoter region from Chip-Atlas. (F) GPSAdb data indicate reduced TRIP13 expression following E2F1 knockdown. Different colors represent different LogFC. (G) PC-3 cells were transfected with specified shRNA for 72 hours, followed by puromycin selection. These cells were treated with collected for ChIP-qPCR analysis using IgG or E2F1 antibodies. Data represent the mean ± SEM from three independent experiments. ** indicates P < 0.01, *** indicates P < 0.001. (H, I) PC-3 and C4-2 cells were transfected with specified shRNA for 72 hours. After puromycin screening, cells were subjected to western blot analysis (H) and RT-qPCR assay (I) . Data represent the mean ± SEM from three independent experiments. ** indicates P < 0.01, *** indicates P < 0.001. (J, K) PC-3 and C4-2 cells were transfected with designated plasmids for 24 hours. Following puromycin screening, cells underwent western blot analysis (J) and RT-qPCR assay (K) . Data are presented as the mean ± SEM from three independent experiments. *** indicates P < 0.001. (L) The sequence and location of the E2F1 binding peak in the TRIP13 promoter. WT, wild type, MUT, mutant. (M) PC-3 cells were transfected with indicated plasmid for 24 h. After puromycin selection, the cells were harvested and the activity of the TRIP13 promoters was measured. Data are presented as the mean ± SEM from three independent experiments. ** indicates P < 0.01, ns, not significant. (N) PC-3 and C4-2 cells were transfected with specified shRNA for 72 hours and indicated plasmid for 24 h, followed by puromycin selection. The cells were then treated with incremental doses of palbociclib for 24 hours and subjected to CCK-8 assays. Data were expressed as the mean ± SEM and repeated three times. Statistical significance was determined using the indicated tests, with P <0.05 considered significant.
    β Actin, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/e2f1/E2F1+Rabbit+pAb/pm41690606-58-75-78
    Average 94 stars, based on 1 article reviews
    β actin - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    86
    Jackson Laboratory e2f1
    <t>E2F1</t> transcriptionally activates TRIP13 to drive Palbociclib resistance in prostate cancer. In TCGA prostate cancer, samples were stratified into high and low TRIP13 expression groups. Differential expression analysis was performed, followed by GSEA enrichment analysis. In the bubble plot, different colors represent NES values, while bubble sizes correspond to the log-adjusted P -values (A) . Spearman correlation plots showing the relationship between E2F1 and TRIP13, panels: (B) TCGA prostate cancer data, (C) PRAD_SU2C_2019 data. (D) Ominer network tool prediction of potential transcription factors for TRIP13. (E) Chip-Seq analysis of E2F1 binding to the TRIP13 promoter region from Chip-Atlas. (F) GPSAdb data indicate reduced TRIP13 expression following E2F1 knockdown. Different colors represent different LogFC. (G) PC-3 cells were transfected with specified shRNA for 72 hours, followed by puromycin selection. These cells were treated with collected for ChIP-qPCR analysis using IgG or E2F1 antibodies. Data represent the mean ± SEM from three independent experiments. ** indicates P < 0.01, *** indicates P < 0.001. (H, I) PC-3 and C4-2 cells were transfected with specified shRNA for 72 hours. After puromycin screening, cells were subjected to western blot analysis (H) and RT-qPCR assay (I) . Data represent the mean ± SEM from three independent experiments. ** indicates P < 0.01, *** indicates P < 0.001. (J, K) PC-3 and C4-2 cells were transfected with designated plasmids for 24 hours. Following puromycin screening, cells underwent western blot analysis (J) and RT-qPCR assay (K) . Data are presented as the mean ± SEM from three independent experiments. *** indicates P < 0.001. (L) The sequence and location of the E2F1 binding peak in the TRIP13 promoter. WT, wild type, MUT, mutant. (M) PC-3 cells were transfected with indicated plasmid for 24 h. After puromycin selection, the cells were harvested and the activity of the TRIP13 promoters was measured. Data are presented as the mean ± SEM from three independent experiments. ** indicates P < 0.01, ns, not significant. (N) PC-3 and C4-2 cells were transfected with specified shRNA for 72 hours and indicated plasmid for 24 h, followed by puromycin selection. The cells were then treated with incremental doses of palbociclib for 24 hours and subjected to CCK-8 assays. Data were expressed as the mean ± SEM and repeated three times. Statistical significance was determined using the indicated tests, with P <0.05 considered significant.
    E2f1, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/e2f1/cg+e2f1/pmc12752754-314-0-4
    Average 86 stars, based on 1 article reviews
    e2f1 - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology anti e2f1
    The <t>E2F1–WDHD1</t> axis promotes malignant phenotypes in pancreatic cancer by upregulating cyclin D1. ( A , B ) Expression of cell cycle-related proteins after knocking down WDHD1. β-actin served as a loading control; Representative images were selected from three independent experiments. ( C ) Expression of CDK4 and cyclin D proteins after overexpression of WDHD1. β-actin served as a loading control. Representative images were selected from three independent experiments. ( D ) RNA expression levels of E2F1 in various pancreatic cancer cell lines show elevated expression compared to normal pancreatic cell lines ( n = 3 independent biological replicates). Summary statistics for each experimental group reported as means ± SD. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 (Student’s t -test), ns, non-significant. ( E , F ) Overexpression of E2F1 can increase the expression of WDHD1 at both the RNA and protein levels ( n = 4 independent biological replicates). Summary statistics for each experimental group reported as means ± SD. Statistical significance: * p < 0.05, *** p < 0.001 (Student’s t -test). β-actin served as a loading control. Representative images were selected from three independent experiments. ( G ) The impact of WDHD1 knockdown after overexpression of E2F1 on cyclin D1, cyclin D3, and CDK4 at protein level. β-actin served as a loading control. Representative images were selected from three independent experiments. ( H ) E2F1 activates the WDHD1 promoter. E2F1 overexpression significantly increased the activity of a luciferase reporter driven by the full-length WDHD1 promoter relative to the vector control, consistent with direct transcriptional activation of WDHD1 by E2F1 ( n = 3 independent biological replicates). Summary statistics for each experimental group reported as means ± SD; Statistical significance: *** p < 0.001 (Student’s t -test). ( I ) ChIP–qPCR shows enrichment of the WDHD1 promoter <t>in</t> <t>anti-E2F1</t> immunoprecipitates relative to IgG control ( n = 3 independent biological replicates). Summary statistics for each experimental group reported as means ± SD; Statistical significance: **** p < 0.0001 (Student’s t -test). The unedited blots can be found in .
    Anti E2f1, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/e2f1/E2F1+Rabbit+mAb/pmc13115010-69-11-12
    Average 94 stars, based on 1 article reviews
    anti e2f1 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    Image Search Results


    E2F1 transcriptionally activates TRIP13 to drive Palbociclib resistance in prostate cancer. In TCGA prostate cancer, samples were stratified into high and low TRIP13 expression groups. Differential expression analysis was performed, followed by GSEA enrichment analysis. In the bubble plot, different colors represent NES values, while bubble sizes correspond to the log-adjusted P -values (A) . Spearman correlation plots showing the relationship between E2F1 and TRIP13, panels: (B) TCGA prostate cancer data, (C) PRAD_SU2C_2019 data. (D) Ominer network tool prediction of potential transcription factors for TRIP13. (E) Chip-Seq analysis of E2F1 binding to the TRIP13 promoter region from Chip-Atlas. (F) GPSAdb data indicate reduced TRIP13 expression following E2F1 knockdown. Different colors represent different LogFC. (G) PC-3 cells were transfected with specified shRNA for 72 hours, followed by puromycin selection. These cells were treated with collected for ChIP-qPCR analysis using IgG or E2F1 antibodies. Data represent the mean ± SEM from three independent experiments. ** indicates P < 0.01, *** indicates P < 0.001. (H, I) PC-3 and C4-2 cells were transfected with specified shRNA for 72 hours. After puromycin screening, cells were subjected to western blot analysis (H) and RT-qPCR assay (I) . Data represent the mean ± SEM from three independent experiments. ** indicates P < 0.01, *** indicates P < 0.001. (J, K) PC-3 and C4-2 cells were transfected with designated plasmids for 24 hours. Following puromycin screening, cells underwent western blot analysis (J) and RT-qPCR assay (K) . Data are presented as the mean ± SEM from three independent experiments. *** indicates P < 0.001. (L) The sequence and location of the E2F1 binding peak in the TRIP13 promoter. WT, wild type, MUT, mutant. (M) PC-3 cells were transfected with indicated plasmid for 24 h. After puromycin selection, the cells were harvested and the activity of the TRIP13 promoters was measured. Data are presented as the mean ± SEM from three independent experiments. ** indicates P < 0.01, ns, not significant. (N) PC-3 and C4-2 cells were transfected with specified shRNA for 72 hours and indicated plasmid for 24 h, followed by puromycin selection. The cells were then treated with incremental doses of palbociclib for 24 hours and subjected to CCK-8 assays. Data were expressed as the mean ± SEM and repeated three times. Statistical significance was determined using the indicated tests, with P <0.05 considered significant.

    Journal: Frontiers in Immunology

    Article Title: Multi-omics analysis and functional validation reveal the oncogenic role of TRIP13

    doi: 10.3389/fimmu.2026.1691436

    Figure Lengend Snippet: E2F1 transcriptionally activates TRIP13 to drive Palbociclib resistance in prostate cancer. In TCGA prostate cancer, samples were stratified into high and low TRIP13 expression groups. Differential expression analysis was performed, followed by GSEA enrichment analysis. In the bubble plot, different colors represent NES values, while bubble sizes correspond to the log-adjusted P -values (A) . Spearman correlation plots showing the relationship between E2F1 and TRIP13, panels: (B) TCGA prostate cancer data, (C) PRAD_SU2C_2019 data. (D) Ominer network tool prediction of potential transcription factors for TRIP13. (E) Chip-Seq analysis of E2F1 binding to the TRIP13 promoter region from Chip-Atlas. (F) GPSAdb data indicate reduced TRIP13 expression following E2F1 knockdown. Different colors represent different LogFC. (G) PC-3 cells were transfected with specified shRNA for 72 hours, followed by puromycin selection. These cells were treated with collected for ChIP-qPCR analysis using IgG or E2F1 antibodies. Data represent the mean ± SEM from three independent experiments. ** indicates P < 0.01, *** indicates P < 0.001. (H, I) PC-3 and C4-2 cells were transfected with specified shRNA for 72 hours. After puromycin screening, cells were subjected to western blot analysis (H) and RT-qPCR assay (I) . Data represent the mean ± SEM from three independent experiments. ** indicates P < 0.01, *** indicates P < 0.001. (J, K) PC-3 and C4-2 cells were transfected with designated plasmids for 24 hours. Following puromycin screening, cells underwent western blot analysis (J) and RT-qPCR assay (K) . Data are presented as the mean ± SEM from three independent experiments. *** indicates P < 0.001. (L) The sequence and location of the E2F1 binding peak in the TRIP13 promoter. WT, wild type, MUT, mutant. (M) PC-3 cells were transfected with indicated plasmid for 24 h. After puromycin selection, the cells were harvested and the activity of the TRIP13 promoters was measured. Data are presented as the mean ± SEM from three independent experiments. ** indicates P < 0.01, ns, not significant. (N) PC-3 and C4-2 cells were transfected with specified shRNA for 72 hours and indicated plasmid for 24 h, followed by puromycin selection. The cells were then treated with incremental doses of palbociclib for 24 hours and subjected to CCK-8 assays. Data were expressed as the mean ± SEM and repeated three times. Statistical significance was determined using the indicated tests, with P <0.05 considered significant.

    Article Snippet: OmicLinkTM Expression Clone (CMV Promoter) plasmids (Catalog #: EX-V0006-M14, GeneCopoeia, USA) were utilized to clone the cDNA of TRIP13 and E2F1 for their overexpression.

    Techniques: Expressing, Quantitative Proteomics, ChIP-sequencing, Binding Assay, Knockdown, Transfection, shRNA, Selection, ChIP-qPCR, Western Blot, Quantitative RT-PCR, Sequencing, Mutagenesis, Plasmid Preparation, Activity Assay, CCK-8 Assay

    The E2F1–WDHD1 axis promotes malignant phenotypes in pancreatic cancer by upregulating cyclin D1. ( A , B ) Expression of cell cycle-related proteins after knocking down WDHD1. β-actin served as a loading control; Representative images were selected from three independent experiments. ( C ) Expression of CDK4 and cyclin D proteins after overexpression of WDHD1. β-actin served as a loading control. Representative images were selected from three independent experiments. ( D ) RNA expression levels of E2F1 in various pancreatic cancer cell lines show elevated expression compared to normal pancreatic cell lines ( n = 3 independent biological replicates). Summary statistics for each experimental group reported as means ± SD. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 (Student’s t -test), ns, non-significant. ( E , F ) Overexpression of E2F1 can increase the expression of WDHD1 at both the RNA and protein levels ( n = 4 independent biological replicates). Summary statistics for each experimental group reported as means ± SD. Statistical significance: * p < 0.05, *** p < 0.001 (Student’s t -test). β-actin served as a loading control. Representative images were selected from three independent experiments. ( G ) The impact of WDHD1 knockdown after overexpression of E2F1 on cyclin D1, cyclin D3, and CDK4 at protein level. β-actin served as a loading control. Representative images were selected from three independent experiments. ( H ) E2F1 activates the WDHD1 promoter. E2F1 overexpression significantly increased the activity of a luciferase reporter driven by the full-length WDHD1 promoter relative to the vector control, consistent with direct transcriptional activation of WDHD1 by E2F1 ( n = 3 independent biological replicates). Summary statistics for each experimental group reported as means ± SD; Statistical significance: *** p < 0.001 (Student’s t -test). ( I ) ChIP–qPCR shows enrichment of the WDHD1 promoter in anti-E2F1 immunoprecipitates relative to IgG control ( n = 3 independent biological replicates). Summary statistics for each experimental group reported as means ± SD; Statistical significance: **** p < 0.0001 (Student’s t -test). The unedited blots can be found in .

    Journal: Current Oncology

    Article Title: E2F1-Driven WDHD1 Transcription Enhances Cell-Cycle Progression and Promotes Pancreatic Cancer Progression

    doi: 10.3390/curroncol33040186

    Figure Lengend Snippet: The E2F1–WDHD1 axis promotes malignant phenotypes in pancreatic cancer by upregulating cyclin D1. ( A , B ) Expression of cell cycle-related proteins after knocking down WDHD1. β-actin served as a loading control; Representative images were selected from three independent experiments. ( C ) Expression of CDK4 and cyclin D proteins after overexpression of WDHD1. β-actin served as a loading control. Representative images were selected from three independent experiments. ( D ) RNA expression levels of E2F1 in various pancreatic cancer cell lines show elevated expression compared to normal pancreatic cell lines ( n = 3 independent biological replicates). Summary statistics for each experimental group reported as means ± SD. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 (Student’s t -test), ns, non-significant. ( E , F ) Overexpression of E2F1 can increase the expression of WDHD1 at both the RNA and protein levels ( n = 4 independent biological replicates). Summary statistics for each experimental group reported as means ± SD. Statistical significance: * p < 0.05, *** p < 0.001 (Student’s t -test). β-actin served as a loading control. Representative images were selected from three independent experiments. ( G ) The impact of WDHD1 knockdown after overexpression of E2F1 on cyclin D1, cyclin D3, and CDK4 at protein level. β-actin served as a loading control. Representative images were selected from three independent experiments. ( H ) E2F1 activates the WDHD1 promoter. E2F1 overexpression significantly increased the activity of a luciferase reporter driven by the full-length WDHD1 promoter relative to the vector control, consistent with direct transcriptional activation of WDHD1 by E2F1 ( n = 3 independent biological replicates). Summary statistics for each experimental group reported as means ± SD; Statistical significance: *** p < 0.001 (Student’s t -test). ( I ) ChIP–qPCR shows enrichment of the WDHD1 promoter in anti-E2F1 immunoprecipitates relative to IgG control ( n = 3 independent biological replicates). Summary statistics for each experimental group reported as means ± SD; Statistical significance: **** p < 0.0001 (Student’s t -test). The unedited blots can be found in .

    Article Snippet: The antibodies utilized in this study included anti-WDHD1 (abclonal, A15396, 1:1000), anti-E2F1 (abclonal, A19579, 1:1000), anti-CDK4 (abclonal, A0366, 1:1000), anti-CDK6 (abclonal, A1545, 1:1000), anti-cyclin D1 (abclonal, A1301, 1:1000), and anti-cyclin D3 (abclonal, A3589, 1:1000). β-actin (ZSGB-BIO, TA-09, 1:1000) was used as the sample loading control.

    Techniques: Expressing, Control, Over Expression, RNA Expression, Knockdown, Activity Assay, Luciferase, Plasmid Preparation, Activation Assay, ChIP-qPCR